Taken together, these data highlight a role for HDAC inhibitors in combination with immunotherapy and provides the rationale to investigate HDAC6 inhibition together with immune checkpoint blockade for treatment of CLL patients. Here, HDAC6 is linked to B-cell chronic lymphocytic leukemia.